The disclosure is directed to compositions comprising a prodrug and an immunomodulator, which can self-assemble into a nanofiber hydrogel at the site of application in a human. The prodrug comprises one or more cytotoxic agents conjugated to a hydrophilic moiety by a linker. The compositions may be used to kill cancer cells, such as glioblastoma and colorectal cancer cells.

Compositions, e.g., compositions comprising protein therapeutics, and methods of using such compositions for treating cancer are described.

The present invention is directed to novel bispecific heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein.

Herein is reported a polypeptide comprising a first polypeptide and a second polypeptide each comprising in N-terminal to C-terminal direction at least a portion of an immunoglobulin hinge region, which comprises one or more cysteine residues, an immunoglobulin CH2-domain and an immunoglobulin CH3-domain, wherein the first, the second, or the first and the second polypeptide comprise the mutation Y436A (numbering according to the EU index).

The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and/or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.

The present disclosure provides multispecific antibodies having increased in vivo sustainability, the multispecific antibodies comprising one or more bioactive effector moieties linked to either or both of an N-terminal and a C-terminal of an antigen binding fragment Fab that binds to human serum albumin.

This disclosure relates to anti-coronavirus (e.g., SARS-CoV-2) antibodies or antigen-binding fragments and uses thereof.

Disclosed herein are anti-SARS-CoV-2 spike protein antibodies and methods of using such for therapeutic and/or diagnostic purposes. Also provided herein are methods for producing such antibodies.

This invention provides humanized IgG4 monoclonal antibodies having the light and heavy chain variable region amino acid sequences of PRO 140, wherein the antibody comprises (i) a heavy chain modification that inhibits half antibody formation, (ii) a heavy chain modification that increases the antibody's terminal half-life, and, optionally, (iii) a heavy chain modification that lowers the antibody's effector function. This invention also provides a related humanized IgG2/IgG4 monoclonal fusion antibody. This invention further provides related nucleic acid molecules; recombinant vectors; recombinant AAV particles; pharmaceutical compositions; prophylactic and therapeutic methods for addressing HIV-1 infection, SARS-CoV-2 infection, and CCR5-mediated disorders; and kits for performing these methods.

Provided are an anti-FXI/FXIa antibody, an antigen-binding fragment thereof, and a pharmaceutical use thereof, as well as a pharmaceutical composition comprising the anti-FXI/FXIa antibody or the antigen-binding fragment thereof, and a method for treating and preventing a disease, in particular a method for treating thrombosis or thromboembolism-related diseases or disorders.